Plasma Exchange in Systemic Lupus Erythematosus. Experience in Thirty-seven Patients

Abstract

Thirty-seven (37) SLE patients submitted to therapeutic plasmapheresis were examined. The results were good in the active stage of the disease. Various types of antibody, anti-DNA, anti nucleus, anti-cardiolipine, I.C. (Clq and C3d) were removed. The values of IgG, coagulation factors, creatinine and proteinuria were assessed. Close collaboration with the clinicians is urged, with the aim of applying immunosuppressive therapy immediately after P.E. to consolidate the results obtained.

A case of thrombocytopoenic thrombotic purpura preceding onset of systemic lupus erythematosus

“…The observation that TTP is more frequent in subjects affected with SLE than in the rest of the population would seem to support this hypothesis.The neurological manifestations may have different origins; given the microangiopathic ischaemic nature of the neurological damage in TTP, some authors propose that in SLE there is a direct harmful action of anti-phospholipid antibodies (APL) on the nerve tissues [4,5]. However, in our experience, in only 2 out of 37 cases of SLE aPL was present, while signs of neurological compromise were present in 9 of 37 patients [6].These observations are mostly derived from cases of subjects affected with SLE, in whom TTP had subsequently arisen after varying periods of time. These studies attempt to find points of contact, despite numerous other aspects which make it difficult to claim an etiopathogenetic link.There is a particular characteristic which distinguishes our case from most of the described cases of concomitant TTP and SLE its chronology.…”

Systemic lupus erythematosus with choroidopathy and serous retinal detachment

“…However, it is often a predictor of a severe underlying systemic disease requiring immunosuppressive agents. Plasma exchanges can be helpful in overcoming the active stage of ocular as well as extraocular manifestations [6].…”

Periodontal Implications: Mucocutaneous Disorders

“…Treatment was given 12 times with a 2 to 3 day interval for a total average dose of 16.5 J/cm2. Of the 16 patients completing the study, PUVA therapy led to marked improvement in 9/16 (56%) of the sites, slight improvement in 4/ 16 (25%) of the sites, and no improvement in 3/16 (19%) of the patients. This contrasted with the control side which exhibited marked improvement in 2/16 (12.5%) of pa-Annals of Periodontology tients, slight improvement in 4/16 (25%) of the sites, and no improvement in 10/16 (62.5%) of the sites.…”

“…Clobetasol Propionate, a high potency topical steroid, was evaluated at a 0.025% concentration in an ointment with orabase.106 Among 9 patients with erosive lichen planus treated 2 to 3 times daily for 2 to 6 weeks, 5/ 9 (55.6%) had complete remission, 2/9 (22.2%) had a good response, and 2/9 (22.2%) did not respond. Lozada Oral Prednisone as a short-term regimen has been evaluated by Silverman et al90 In 19 lichen planus patients treated with 40 to 60 mg/day for less than 2 weeks, 2/19 (11%) were symptom-free, 16/19 (84%) had reduced symptoms, and 1/19 (5%) had no significant response. This contrasted to another study of 118 treated only topically with 0.05% fluocinonide in an orabase paste.…”